Monthly Archives: March 2012

FDA discussion: Evaluation of the Cardiac Safety for Serotonin Receptor Agonists as GI Therapies.

Posted on 20 March 2012 by ERTglobal

Written by: Dr. Robert Kleiman, Chief Medical Officer & Vice President, Global Cardiology A few months ago in November 2011, the FDA brought together a group of gastroenterologists and cardiologists to discuss the history of cardiac safety issues surrounding serotonin 5-HT4 … Continue reading →